PL1893620T3 - Podstawione spiro-związki i ich zastosowanie do wytwarzania przeciwbólowych środków leczniczych - Google Patents

Podstawione spiro-związki i ich zastosowanie do wytwarzania przeciwbólowych środków leczniczych

Info

Publication number: PL1893620T3
Authority: PL; Poland
Prior art keywords: aliphatic compound; gen; optionally substituted; cycloaliphatic group; diastereomer
Prior art date: 2005-05-19

Application number

PL06742950T

Other languages

English (en)

Inventor

Hans Schick

Robert Frank

Melanie Reich

Ruth Jostock

Gregor Bahrenberg

Fritz Theil

Birgitta Henkel

Original Assignee

Gruenenthal Gmbh

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2005-05-19

Filing date

2006-05-17

Publication date

2012-02-29

2006-05-17 Application filed by Gruenenthal Gmbh filed Critical Gruenenthal Gmbh

2012-02-29 Publication of PL1893620T3 publication Critical patent/PL1893620T3/pl

Links

150000003413 spiro compounds Chemical class 0.000 title abstract 3
239000003814 drug Substances 0.000 title 1
229940079593 drug Drugs 0.000 title 1
150000007824 aliphatic compounds Chemical class 0.000 abstract 6
125000003118 aryl group Chemical group 0.000 abstract 3
125000005842 heteroatom Chemical group 0.000 abstract 3
125000005843 halogen group Chemical group 0.000 abstract 2
239000000203 mixture Substances 0.000 abstract 2
150000003839 salts Chemical class 0.000 abstract 2
239000012453 solvate Substances 0.000 abstract 2
208000030814 Eating disease Diseases 0.000 abstract 1
208000019454 Feeding and Eating disease Diseases 0.000 abstract 1
208000001953 Hypotension Diseases 0.000 abstract 1
229940122936 Vanilloid receptor 1 agonist Drugs 0.000 abstract 1
230000001195 anabolic effect Effects 0.000 abstract 1
230000000202 analgesic effect Effects 0.000 abstract 1
230000000954 anitussive effect Effects 0.000 abstract 1
230000001539 anorectic effect Effects 0.000 abstract 1
230000001088 anti-asthma Effects 0.000 abstract 1
230000001773 anti-convulsant effect Effects 0.000 abstract 1
230000001430 anti-depressive effect Effects 0.000 abstract 1
230000003110 anti-inflammatory effect Effects 0.000 abstract 1
230000002460 anti-migrenic effect Effects 0.000 abstract 1
230000000648 anti-parkinson Effects 0.000 abstract 1
230000001139 anti-pruritic effect Effects 0.000 abstract 1
239000000924 antiasthmatic agent Substances 0.000 abstract 1
239000001961 anticonvulsive agent Substances 0.000 abstract 1
239000000935 antidepressant agent Substances 0.000 abstract 1
229940005513 antidepressants Drugs 0.000 abstract 1
229960003965 antiepileptics Drugs 0.000 abstract 1
239000000939 antiparkinson agent Substances 0.000 abstract 1
239000003908 antipruritic agent Substances 0.000 abstract 1
229940124584 antitussives Drugs 0.000 abstract 1
230000001966 cerebroprotective effect Effects 0.000 abstract 1
206010061428 decreased appetite Diseases 0.000 abstract 1
PCHPORCSPXIHLZ-UHFFFAOYSA-N diphenhydramine hydrochloride Chemical compound [Cl-].C=1C=CC=CC=1C(OCC[NH+](C)C)C1=CC=CC=C1 PCHPORCSPXIHLZ-UHFFFAOYSA-N 0.000 abstract 1
230000000694 effects Effects 0.000 abstract 1
208000021822 hypotensive Diseases 0.000 abstract 1
230000001077 hypotensive effect Effects 0.000 abstract 1
239000002955 immunomodulating agent Substances 0.000 abstract 1
229940121354 immunomodulator Drugs 0.000 abstract 1
230000002584 immunomodulator Effects 0.000 abstract 1
230000010534 mechanism of action Effects 0.000 abstract 1
230000000324 neuroprotective effect Effects 0.000 abstract 1
230000001777 nootropic effect Effects 0.000 abstract 1
125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 1
229940125725 tranquilizer Drugs 0.000 abstract 1
239000003204 tranquilizing agent Substances 0.000 abstract 1
230000002936 tranquilizing effect Effects 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/10—Spiro-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/06—Anti-spasmodics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
Veterinary Medicine (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Addiction (AREA)
Psychiatry (AREA)
Pain & Pain Management (AREA)
Diabetes (AREA)
Hematology (AREA)
Pulmonology (AREA)
Dermatology (AREA)
Rheumatology (AREA)
Urology & Nephrology (AREA)
Psychology (AREA)
Ophthalmology & Optometry (AREA)
Immunology (AREA)
Vascular Medicine (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Obesity (AREA)
Child & Adolescent Psychology (AREA)
Hospice & Palliative Care (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Nutrition Science (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

PL06742950T 2005-05-19 2006-05-17 Podstawione spiro-związki i ich zastosowanie do wytwarzania przeciwbólowych środków leczniczych PL1893620T3 (pl)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
DE102005023784A DE102005023784A1 (de)	2005-05-19	2005-05-19	Substituierte Spiro-Verbindungen und deren Verwendung zur Herstellung von Arzneimitteln
PCT/EP2006/004651 WO2006122769A2 (de)	2005-05-19	2006-05-17	Substituierte spiro-verbindungen und deren verwendung zur herstellung von arzneimitteln gegen schmerz
EP06742950A EP1893620B1 (de)	2005-05-19	2006-05-17	Substituierte spiro-verbindungen und deren verwendung zur herstellung von arzneimitteln gegen schmerz

Publications (1)

Publication Number	Publication Date
PL1893620T3 true PL1893620T3 (pl)	2012-02-29

Family

ID=36646208

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
PL10012043T PL2292625T3 (pl)	2005-05-19	2006-05-17	Podstawione spiro-związki i ich zastosowanie do wytwarzania przeciwbólowych środków leczniczych
PL06742950T PL1893620T3 (pl)	2005-05-19	2006-05-17	Podstawione spiro-związki i ich zastosowanie do wytwarzania przeciwbólowych środków leczniczych

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
PL10012043T PL2292625T3 (pl)	2005-05-19	2006-05-17	Podstawione spiro-związki i ich zastosowanie do wytwarzania przeciwbólowych środków leczniczych

Country Status (13)

Country	Link
US (1)	US20080214807A1 (pl)
EP (2)	EP2292625B1 (pl)
JP (1)	JP5376941B2 (pl)
AT (1)	ATE524478T1 (pl)
CA (1)	CA2608385A1 (pl)
CY (1)	CY1112137T1 (pl)
DE (1)	DE102005023784A1 (pl)
DK (1)	DK1893620T3 (pl)
ES (2)	ES2447815T3 (pl)
PL (2)	PL2292625T3 (pl)
PT (1)	PT1893620E (pl)
SI (1)	SI1893620T1 (pl)
WO (1)	WO2006122769A2 (pl)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE102005044813A1 (de)	2005-05-19	2007-10-04	Grünenthal GmbH	Substituierte Spiro-Verbindungen und deren Verwendung zur Herstellung von Arzneimitteln
EP2064187A2 (en) *	2006-08-25	2009-06-03	Vitae Pharmaceuticals, Inc.	Inhibitors of 11beta-hydroxysteroid dehydrogenase type 1
WO2009108332A1 (en)	2008-02-27	2009-09-03	Vitae Pharmaceuticals, Inc.	INHIBITORS OF 11β -HYDROXYSTEROID DEHYDROGENASE TYPE 1
US8349852B2 (en)	2009-01-13	2013-01-08	Novartis Ag	Quinazolinone derivatives useful as vanilloid antagonists
US8765735B2 (en) *	2009-05-18	2014-07-01	Infinity Pharmaceuticals, Inc.	Isoxazolines as inhibitors of fatty acid amide hydrolase
WO2011092293A2 (en)	2010-02-01	2011-08-04	Novartis Ag	Cyclohexyl amide derivatives as crf receptor antagonists
AR080055A1 (es)	2010-02-01	2012-03-07	Novartis Ag	Derivados de pirazolo-[5,1-b]-oxazol como antagonistas de los receptores de crf -1
ES2527849T3 (es)	2010-02-02	2015-01-30	Novartis Ag	Derivados de ciclohexilamida como antagonistas del receptor de CRF
MX379359B (es)	2016-01-13	2025-03-11	Gruenenthal Gmbh	Derivados de 8-amino-2-oxo-1,3-diaza-espiro-[4.5]-decano.
DK3402785T3 (da)	2016-01-13	2020-04-20	Gruenenthal Gmbh	3-(carboxymethyl)-8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decan-derivater
AU2017206908B2 (en)	2016-01-13	2020-07-09	Grünenthal GmbH	3-((hetero-)aryl)-8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decane derivatives

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0888344A1 (en) *	1996-03-15	1999-01-07	The Du Pont Merck Pharmaceutical Company	Spirocycle integrin inhibitors
WO1998043962A1 (en) *	1997-03-28	1998-10-08	Du Pont Pharmaceuticals Company	Heterocyclic integrin inhibitor prodrugs
DK1075277T4 (da) *	1998-05-08	2012-12-17	Univ California	Fremgangsmåder til detektion og inhibering af angiogenese
DE10130020A1 (de) *	2001-06-25	2003-12-04	Gruenenthal Gmbh	Substituierte 1-Oxa-2,8-diaza-spiro[4.5]dec-2-en-derivate
ATE533743T1 (de) *	2002-05-17	2011-12-15	Janssen Pharmaceutica Nv	Harnstoffderivate von aminotetralin als modulatoren des vanilloid-rezeptors vr1
PL375552A1 (pl) *	2002-05-22	2005-11-28	Amgen Inc.	Ligandy receptora waniloidowego oraz ich medycznezastosowania
DE102004032567A1 (de) *	2004-07-05	2006-03-02	Grünenthal GmbH	Substituierte 1-Propiolyl-piperazine

2005
- 2005-05-19 DE DE102005023784A patent/DE102005023784A1/de not_active Withdrawn
2006
- 2006-05-17 CA CA002608385A patent/CA2608385A1/en not_active Abandoned
- 2006-05-17 SI SI200631204T patent/SI1893620T1/sl unknown
- 2006-05-17 ES ES10012043.5T patent/ES2447815T3/es not_active Expired - Lifetime
- 2006-05-17 US US11/914,866 patent/US20080214807A1/en not_active Abandoned
- 2006-05-17 EP EP10012043.5A patent/EP2292625B1/de not_active Expired - Lifetime
- 2006-05-17 DK DK06742950.6T patent/DK1893620T3/da active
- 2006-05-17 PT PT06742950T patent/PT1893620E/pt unknown
- 2006-05-17 WO PCT/EP2006/004651 patent/WO2006122769A2/de not_active Ceased
- 2006-05-17 ES ES06742950T patent/ES2370038T3/es not_active Expired - Lifetime
- 2006-05-17 PL PL10012043T patent/PL2292625T3/pl unknown
- 2006-05-17 PL PL06742950T patent/PL1893620T3/pl unknown
- 2006-05-17 JP JP2008511619A patent/JP5376941B2/ja not_active Expired - Fee Related
- 2006-05-17 EP EP06742950A patent/EP1893620B1/de not_active Expired - Lifetime
- 2006-05-17 AT AT06742950T patent/ATE524478T1/de active
2011
- 2011-12-05 CY CY20111101204T patent/CY1112137T1/el unknown

Also Published As

Publication number	Publication date
CY1112137T1 (el)	2015-11-04
WO2006122769A3 (de)	2007-03-15
ES2447815T3 (es)	2014-03-13
WO2006122769A2 (de)	2006-11-23
PL2292625T3 (pl)	2014-04-30
EP1893620B1 (de)	2011-09-14
DE102005023784A1 (de)	2006-11-30
ATE524478T1 (de)	2011-09-15
DK1893620T3 (da)	2012-01-16
SI1893620T1 (sl)	2012-04-30
ES2370038T3 (es)	2011-12-12
JP5376941B2 (ja)	2013-12-25
PT1893620E (pt)	2011-10-31
EP2292625B1 (de)	2013-12-25
CA2608385A1 (en)	2006-11-23
EP2292625A1 (de)	2011-03-09
JP2008540592A (ja)	2008-11-20
US20080214807A1 (en)	2008-09-04
EP1893620A2 (de)	2008-03-05

Publication	Publication Date	Title
CY1112137T1 (el)	2015-11-04	Υποκατεστημενες σπειρο-ενωσεις και η χρηση αυτων για παραγωγη φαρμακευτικων μεσων εναντι πονου
AU2011215704B2 (en)	2015-07-23	Secondary structure stabilized NMDA receptor modulators and uses thereof
US5804595A (en)	1998-09-08	Kappa opioid receptor agonists
PL378288A1 (pl)	2006-03-20	Nowe pochodne benzoimidazolu oraz imidazo-pirydyny oraz ich zastosowanie jako leków
CA2523261A1 (en)	2004-11-18	Fused pyrimidine derivatives with crf activity
US9603889B2 (en)	2017-03-28	IAP antagonists
EP2331571A1 (en)	2011-06-15	Nmda receptor modulators and uses thereof
MX2007007220A (es)	2007-08-20	Compuestos de pirazolona como agonistas de receptor de glutamato metabotropico para el tratamiento de trastornos neurologicos y psiquiatricos.
EA200400762A1 (ru)	2004-12-30	Новые соединения, их использование в медицине, способ их изготовления и содержащие их фармацевтические композиции
MY138086A (en)	2009-04-30	Novel urea derivative as vanilloid receptor-1 antagonist
JP2015505296A (ja)	2015-02-19	Ｎｍｄａ受容体調節剤およびその使用
SE9904508D0 (sv)	1999-12-09	New compounds
PT1910381E (pt)	2009-09-09	Compostos substituídos de 1-oxa-3,8-diazaspiro[4.5]decan-2- ona e sua utilização para produção de fármacos
Wrobleski et al.	2006	Cyclobutane derivatives as potent NK1 selective antagonists
SE0102055D0 (sv)	2001-06-08	New Compounds
AR048973A1 (es)	2006-06-14	(4-metoxi-7-morfolin-4-il-benzotiazol-2-il)amida del acido 4-hidroxi-4-metil-piperidin-1-carboxilico. proceso de preparacion y composiciones farmaceuticas
CY1110613T1 (el)	2015-04-29	Υποκατεστημενες θειαζολες και η χρησιμοποιηση τους για την παρασκευη φαρμακων
MXPA05011521A (es)	2006-01-23	Derivado de 4,4-difluoro-1,2,3,4-tetrahidro-5h-1-benzazepina o una sal del mismo.
CA2490002A1 (en)	2003-12-31	Novel tetracyclic arylcarbonyl indoles having serotonin receptor affinity useful as therapeutic agents, process for their preparation and pharmaceutical compositions containing them
SG146692A1 (en)	2008-10-30	Melanin concentrating hormone antagonists
Liu et al.	2010	A mild and efficient synthesis of monofluorinated α-lactam pseudopeptides via a novel dehydrofluorination of Ugi products
Paliwal et al.	2008	Discovery of a novel, potent and orally active series of γ-lactams as selective NK1 antagonists
US20120309811A1 (en)	2012-12-06	P-glycoprotein-specific non-competitive peptide and peptidomimetic modulators
Röhr et al.	2001	Synthesis and stereoselective κ-receptor binding of methylated analogues of GR-89.696
EA015500B9 (ru)	2012-03-30	Новые антагонисты мсн рецепторов